Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ansys Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Drugs-of-abuse testing firm's proposed initial public offering of 2.5 mil. shares at $10-12 each is outlined in a prospectus filed with the Securities and Exchange Commission. A portion of the approximately $25 mil. in anticipated net proceeds will be used for repayment of bank debt, manufacturing improvements, increased R&D expenditures, acquisitions and general corporate purposes. For the on-site drug testing market, Lake Forest, California-based Ansys produces for Roche Diagnostic Systems the TesTcup and TesTstik urine-based testing devices for detection of drugs-of-abuse. The company also makes the On-Site Alcohol pocket-sized test for detection of ethanol in urine or saliva. For the laboratory market, the firm offers the Toxi-Lab drug screening system, specialty laboratory and research products. The drugs-of-abuse testing segment of the U.S. in vitro diagnostic testing market was about $628 mil. in 1996 and is estimated to grow to about $900 mil. by 2002. In 1998, the company generated net income of $2.7 mil. (up 123%) on revenues of $19 mil. (up 77.3%). Underwriters Vector Securities International and Sutro & Co. hold an overallotment option for 375,000 additional shares

You may also be interested in...



Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

UsernamePublicRestriction

Register

MT011450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel